Summary
We have given single high doses of dexamethasone phosphate by intravenous infusion as an antiemetic to 15 cancer patients receiving regimens containing cisplatin and/or doxorubicin. The patients received graded doses of dexamethasone phosphate, in the range 40–200 mg, dependent upon nausea and vomiting scores, during up to three consecutive cycles of cancer chemotherapy. Plasma and urine concentrations of dexamethasone (dexamethasone alcohol) were measured by HPLC.
The plasma concentration-time data were described by an open two-compartment model. The pharmacokinetic variables were independent of the dose of dexamethasone over the range studied. The terminal half-time was 4.0±0.4 h and the total body clearance was 3.5±0.4 ml·min−1·kg−1. The volume of the central compartment and the total apparent volume of distribution were 0.23±0.03 and 1.0±0.1 l·kg−1 respectively. Approximately 8% of the dose was excreted into the urine as dexamethasone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 7: 11–14
Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED (1984) Antiemetic efficacy of dexamethasone. N Engl J Med 311: 549–552
Zaglama NE, Rosenblum SL, Sartiano GP, Brady ME, Gonzalez MF, Valdivieso JG (1986) Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 43: 27–32
Baker JJ, Lokey JL, Price NA, Bowen J, Winokur SH, (1980) Comparison of dexamethasone plus prochlorperazine to placebo plus prochorperazine as antiemetics for cancer chemotherapy. Proc. Am Ass Cancer Res Am Soc Clin Oncol 21: 339
Bruera ED, Roca E, Cedaro L, Chacon R, Estevez R (1983) Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 67: 381–383
Cassileth PA, Lusk EJ, Torri S, Gerson SL (1984) Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia. Ann Intern Med 100: 701–702
Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, Groshen S, Bosl GJ, Kalman LA (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 55: 527–534
Strum SB, McDermed JE, Streng BR, McDermott NM (1984) Combination metoclopramide and dexamethasone: An effective antiemetic regimen in outpatients receiving non-cisplatin chemotherapy. J Clin Oncol 2: 1057–1063
Miyabo S, Nakamura, T, Kuwazima S, Kishida S (1981) A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man. Eur J Clin Pharmacol 20: 277–282
Rose JQ, Yurchak AM, Meikle AW, Jusko WJ (1981) Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. J Pharmacokinet Biopharm 9: 1–14
Tsuei SE, Moore RG, Ashley JJ, McBride WG (1979) Disposition of synthetic glucocorticoids: I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 7: 249–264
Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562
Loo JCK, Riegelman S (1970) Assessment of pharmacokinetic constants from post infusion blood curves after IV infusion. J Pharm Sci 59: 53–55
Duggan DE, Yeh KC, Matalia N, Ditzler CA, McMahon FG (1975) Bioavailability of dexamethasone: II. Dexamethasone phosphate. Clin Pharmacol Ther 18: 330–337
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brady, M.E., Sartiano, G.P., Rosenblum, S.L. et al. The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 32, 593–596 (1987). https://doi.org/10.1007/BF02455994
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02455994